Adoptive transfer of chimeric antigen receptor (CAR) T cell-based therapies has demonstrated promising results across multiple cancer types. The emergence of CAR and engineered T cell receptor (TCR) T cell-based immunotherapy has forever changed the treatment landscape, but not without introducing new hurdles. Research shows to achieve improved clinical outcomes, engineered CAR/TCR T cells require optimal potency and metabolic fitness obtained through genetic modification or metabolic preconditioning parameters. Probing a wide range of conditions and modifications with gold standard endpoint assays, however, can be tedious and inefficient. There are currently no clinical processes in place to directly assess the metabolic fitness of CAR/TCR T cells.
This webinar presents a comprehensive real-time workflow to evaluate T-cell potency and metabolic fitness by combining two of Agilent’s powerful Cell Analysis instruments. Using the xCELLigence RTCA principle of cellular impedance, the eSight provides an exquisitely sensitive and information-rich interrogation of T cell potency by coupling real-time impedance with live cell imaging to elucidate mechanism of action. Concurrent use of Seahorse technology quantitively measures metabolic fitness along with potency to provide an orthogonal data read out.
Register now to hear how the RTCA eSight and Seahorse XF-Pro are combined to investigate the impact of metabolic preconditioning on the killing efficacy and metabolic fitness of MART-1 specific TCR T cells at elevated amino acid concentrations in one simple workflow. Learn how to save time and boost efficiency in your cell therapy process development!
The learning objectives of this webinar include:
Dr. Rashmi Pillai is a research scientist in the Cell Analysis Division at Agilent Technologies. Her focus is on developing multiplatform workflows using xCELLigence, Seahorse, and NovoCyte within the immunotherapy field. Her experience encompasses more than 17 years of cancer research and 20 peer-reviewed publications/abstracts at international meetings. She received her Ph.D. degree in Biochemistry from the University of Kerala in 2004. Her doctoral studies focused on therapy resistance and ways to overcome chemo-resistance in curcumin-based therapy. In 2005, Dr. Pillai joined Saint Louis University in St Louis, MO as an NIH postdoctoral fellow. Her research focused on defects in cellular death pathways as a contributing mechanism for chemo-resistance and inflammation. Later as a senior scientist at Washington University School of Medicine, she explored the metabolic plasticity of tumor cells as a model to identify personalized treatment for cervical cancer.